COVID-19 Vaccine of the Vector Center has Shown High Efficiency in Preclinical Trials

26 August 2020

GMP News

The anti-coronavirus vaccine developed by the Vektor State Research Center of Virology and Biotechnology of the Russian sanitary regulator has proved its high efficiency during preclinical trials, Rinat Maksyutov, the center’s director, said in an interview with the Rossiiskaya Gazeta.

“The Vektor Center’s unique peptide-based vaccine has demonstrated high efficiency during preclinical tests and is now undergoing clinical trials,” he said, adding that the center had referred two interim reports about the results of the first stage of trials to the health ministry.

According to Maksyutov, all participants in the trials feel well. “The first volunteer was inoculated for the second time and left the hospital 21 days later. Now we are monitoring his condition in the outpatient regime. He will visit the hospital in three, six and nine months,” he said.

Russia’s sanitary watchdog said the vaccine’s clinical tests would be over in September. It is planned to register the vaccine in October 2020 and begin mass production in November.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more